{"name":"Advenchen Pharmaceuticals, LLC.","slug":"advenchen-pharmaceuticals-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"AL8326 low dose group","genericName":"AL8326 low dose group","slug":"al8326-low-dose-group","indication":"Type 2 diabetes","status":"phase_2"},{"name":"AL8326 middle dose group","genericName":"AL8326 middle dose group","slug":"al8326-middle-dose-group","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AL8326 high dose group","genericName":"AL8326 high dose group","slug":"al8326-high-dose-group","indication":"Inflammatory airway disease (Phase 2 development)","status":"phase_2"}]}],"pipeline":[{"name":"AL8326 high dose group","genericName":"AL8326 high dose group","slug":"al8326-high-dose-group","phase":"phase_2","mechanism":"AL8326 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Inflammatory airway disease (Phase 2 development)"],"catalyst":""},{"name":"AL8326 low dose group","genericName":"AL8326 low dose group","slug":"al8326-low-dose-group","phase":"phase_2","mechanism":"AL8326 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"AL8326 middle dose group","genericName":"AL8326 middle dose group","slug":"al8326-middle-dose-group","phase":"phase_2","mechanism":"AL8326 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPNjJBXzE5X0pwT3BfalJmLUZ4djRzczM5UEFnWldGSzl6Mkl3Rl81M09wODBaaFBmczNDNkxMWS1Ib05SeV9hUS0zLVZGc05LcnJHYk5OMk9MS3RGVDBKMVR1M1ZhRjdyMVdsbloxYzVnaTJiVlZaaDlfVThseFpSVDRnelUwLVUtUERIVEo5ZUV5b1daclQ2T2d0eFlkWWJaY2dSNWNIcWJsTmdvMDlzdUFacTZ5czczX19CX1dvbS13OV9wZ0lxOHBNWXYtc0RhWXNQNjlBdGpzaGZ4eklUQmNIX3Q3ZXN2ejczZzNlSHo4YWg5aVcyeDBYUjktdlE?oc=5","date":"2025-10-20","type":"pipeline","source":"PR Newswire","summary":"Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsight - PR Newswire","headline":"Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxORHo3M2p3MHhUWW44b2l4WU95VWc0eGJERzFkSWEzempiUDgtbjA0bGk5cmp3U21DdVJMVFdtUVN4VGs2U2Z5aURnUVFhVUZ0U2l5TUZJQ29fZUwtX0d0d05xc051MDZFV2cwa3c4MmZOQ0J4WWZ4UWlYYlZCTFNPVWMzS1FwWm1HQXMyTDBGNGR2QUZnZ2c?oc=5","date":"2024-05-17","type":"regulatory","source":"Fierce Pharma","summary":"FDA snubs another China-made PD-1 with rejection of Elevar, Hengrui's liver cancer combo - Fierce Pharma","headline":"FDA snubs another China-made PD-1 with rejection of Elevar, Hengrui's liver cancer combo","sentiment":"negative"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}